MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy

Medicine and Dentistry

• Ras 100%
• Epidermal Growth Factor Receptor 85%
• Pimasertib 71%
• Selumetinib 71%
• Cetuximab 57%
• In Vitro 42%
• Monoclonal Antibody 42%
• MEK Inhibitor 28%
• Monoclonal Antibody Therapy 28%
• Panitumumab 28%
• Cancer Cell 14%
• Phosphotransferase 14%
• Tumor Xenograft 14%
• Tumor Cell Line 14%
• Colorectal Tumor 14%
• Patient Care 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Epidermal Growth Factor Receptor 85%
• Pimasertib 71%
• Selumetinib 71%
• Cetuximab 57%
• Monoclonal Antibody 42%
• Colorectal Cancer 42%
• Panitumumab 28%
• Mitogen Activated Protein Kinase Kinase Inhibitor 28%
• Phosphotransferase 14%
• Metastatic Colorectal Cancer 14%
• Colorectal Tumor 14%

Agricultural and Biological Sciences

• Epidermal Growth Factor Receptor 100%
• Cetuximab 50%
• Monoclonal Antibody 50%
• Mutation 33%
• Monoclonal Antibody Therapy 33%
• Cell Lines 16%
• Clinical Trials 16%
• Panitumumab 16%
• KRAS 16%
• Patient Care 16%